Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension
![Thumbnail](/bitstream/handle/10454/18507/Nasim_et_al_TPS.pdf.jpg?sequence=7&isAllowed=y)
View/ Open
Nasim_et_al_TPS.pdf (298.2Kb)
Download
Publication date
2021-07Rights
© 2021 Elsevier Ltd. All rights reserved. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license.Peer-Reviewed
YesOpen Access status
openAccessAccepted for publication
2021-04-07
Metadata
Show full item recordAbstract
Aberrant transforming growth factor-β (TGF-β) signaling activation is linked to pulmonary arterial hypertension (PAH). BMPR2 mutations perturb the balance between bone morphogenetic protein (BMP) and TGF-β pathways, leading to vascular remodeling, narrowing of the lumen of pulmonary vasculature, and clinical symptoms. This forum highlights the association of the TGF-β pathway with pathogenesis and therapeutic approaches.Version
Accepted manuscriptCitation
Sharmin N, Nganwuchu CC and Nasim Md T (2021) Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension. Trends in Pharmacological Sciences. 42(7): 510-513.Link to Version of Record
https://doi.org/10.1016/j.tips.2021.04.002Type
Articleae974a485f413a2113503eed53cd6c53
https://doi.org/10.1016/j.tips.2021.04.002